Results 11 to 20 of about 22,677 (265)

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants. [PDF]

Clin Transl Sci
ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Kim JD, Metzger IF, Lu JBL, Skaar TC, Desta Z.   +4 more
europepmc   +2 more sources

Effects of Botrychium ternatum (Thunb) Sw. On Cytochrome P450 Activities in Rats. [PDF]

Pharmacol Res Perspect
Pharmacokinetic effects of Botrychium ternatum (Thunb) Sw. on cytochrome P450 activities. ABSTRACT Drug interactions commonly occur through the activities of cytochrome P450 (CYP). In this study, we evaluated the effects of the Chinese herbal medicine Botrychium Ternatum (Thunb) Sw. (BT) on six CYP enzymes.
Yao J, Hu L, Zhou Q, Al Mamun A, Wang S, Han A.   +5 more
europepmc   +2 more sources

Evaluation of the Pharmacokinetics, Disposition, and Metabolism of Miricorilant, a Novel Glucocorticoid Receptor Modulator for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in Nonclinical and Clinical Studies. [PDF]

J Clin Pharmacol
Abstract Miricorilant is a novel selective glucocorticoid receptor (GR) modulator with mixed agonist/antagonist effects at the GR and modest antagonism at the mineralocorticoid receptor that is being developed for the treatment of metabolic dysfunction‐associated steatohepatitis.
Hunt HJ, Donaldson KM, Kunta JR, Custodio JM.   +3 more
europepmc   +2 more sources

Gαs defines the fundamental coupling mechanism of insulin secretion. [PDF]

J Diabetes Investig
Journal of Diabetes Investigation, Volume 17, Issue 1, Page 9-11, January 2026.
Shirakawa J.
europepmc   +2 more sources

Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method

Frontiers in Pharmacology, 2021
Poziotinib is an orally active, irreversible, pan-HER tyrosine kinase inhibitor used to treat non-small cell lung cancer, breast cancer, and gastric cancer.
Jinhui Wang, Feifei Chen, Hui Jiang, Jia Xu, Deru Meng, Peiwu Geng, Dapeng Dai, Jingbo Hu, Yunfang Zhou, Quan Zhou, Shuanghu Wang   +10 more
doaj   +1 more source

ATP-gated potassium channels contribute to ketogenic diet-mediated analgesia in mice

Neurobiology of Pain, 2023
Chronic pain is a substantial health burden and options for treating chronic pain remain minimally effective. Ketogenic diets are emerging as well-tolerated, effective therapeutic strategies in preclinical models of chronic pain, especially diabetic ...
Jonathan D. Enders, Sarah Thomas, Paige Lynch, Jarrid Jack, Janelle M. Ryals, Patrycja Puchalska, Peter Crawford, Douglas E. Wright   +7 more
doaj   +1 more source

Quantitation of Diclofenac, Tolbutamide, and Warfarin as Typical CYP2C9 Substrates in Rat Plasma by UPLC-MS/MS and Its Application to Evaluate Linderane-Mediated Herb-Drug Interactions

Journal of Analytical Methods in Chemistry, 2022
Linderane (LDR), the main active and distinctive component of L. aggregate, is a mechanism-based inactivator of CYP2C9 in vitro, indicating the occurrence of herb-drug interactions.
Tingting Zhang, Ting Peng, Jinqiu Rao, Kai Wang, Feng Qiu   +4 more
doaj   +1 more source

Influence of antioxidant (L- ascorbic acid) on tolbutamide induced hypoglycaemia/antihyperglycaemia in normal and diabetic rats

BMC Endocrine Disorders, 2005
Background Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycaemia. Increased oxidative stress and decreased antioxidant levels are the leading cause of diabetes and diabetic complications.
Vardhan Vishnu A, Kilari Eswar K, Sreemantula Satyanarayana, Jaladi Rajasekhar   +3 more
doaj   +1 more source

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo

Frontiers in Pharmacology, 2020
BackgroundVonoprazan fumarate is a potassium-competitive acid blocker that was developed as a novel acid-suppressing drug for multiple indications. As a potential alternative to proton-pump inhibitors, the determination of the drug-drug interactions is ...
Yiran Wang, Changxiong Wang, Shuanghu Wang, Quan Zhou, Dapeng Dai, Jihua Shi, Xue Xu, Qingfeng Luo   +7 more
doaj   +1 more source

Cromakalim (BRL 34915) restores in vitro the membrane potential of depolarized human skeletal muscle fibres [PDF]

, 1989
The purpose of the present study was to analyze the effects of cromakalim (BRL 34915), a potent drug from a new class of drugs characterized as K+ channel openers, on the electrical activity of human skeletal muscle.
Grafe, Peter, Lehmann-Horn, Frank, Spuler, A.   +2 more
core   +1 more source